MVIR Share Price Performance
SEK 1.90
-0.16 (-7.54%)
65.3% undervalued intrinsic discount
SEK 5.47
Fair Value
Price SEK 1.90
AnalystConsensusTarget SEK 5.47
AnalystHighTarget SEK 6.86
AnalystLowTarget SEK 4.00
Fair ValueSEK 5.47
Share Pricen/a
Medivir AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
MVIR Community Narratives
AN
Fair Value
·Fair Value SEK 5.47 65.3% undervalued intrinsic discount
Liver Cancer Trial Progress And Rights Issue Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value SEK 6.86 72.3% undervalued intrinsic discount
Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 4 52.5% undervalued intrinsic discount
Rare Disease And Liver Cancer Setbacks Will Test This High Risk Pipeline Story
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Liver Cancer Trial Progress And Rights Issue Will Drive Long Term Upside Potential
Medivir is pushing its lead liver cancer drug into a tougher mid-stage study, aiming to help patients who don’t respond to today’s first-choice treatments. A planned cash raise and a partnered skin-cancer program could buy time to reach key trial results, but the bet hinges on the next study showing clear benefits and safe use.Read more
AN
SEK 5.47
65.3% undervalued intrinsic discount
Fair Value
Profit Margin
20.95%
Future PE
262.36x
Price in 2029
SEK 3.57
Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects
Catalysts About Medivir Medivir is a biotech company focused on developing first in class therapies in oncology and rare bone diseases, alongside partnered programs in animal health. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 6.86
72.3% undervalued intrinsic discount
Fair Value
Profit Margin
20.1%
Future PE
2.24kx
Price in 2029
SEK 4.46
Rare Disease And Liver Cancer Setbacks Will Test This High Risk Pipeline Story
Catalysts About Medivir Medivir is a research based pharmaceutical company focused on developing first in class therapies for oncology and rare bone disorders. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 4
52.5% undervalued intrinsic discount
Fair Value
Profit Margin
20.1%
Future PE
1.35kx
Price in 2029
SEK 2.6
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
MVIR: Future Equity Raises And Liver Cancer Data Will Drive Repricing
Fair Value: SEK 5.47 65.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects
Fair Value: SEK 6.86 72.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease And Liver Cancer Setbacks Will Test This High Risk Pipeline Story
Fair Value: SEK 4 52.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Medivir AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
- -0.14
- -383.15%
- -1,038.54%
- 0%
About MVIR
- Founded
- 1987
- Employees
- 7
- CEO
- WebsiteView website
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
